Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

‘Casodex’ (bicalutamide) 150mg a cost effective treatment for the management of locally advanced prostate cancer[1]

18.01.2005


New health economic data published in the European Journal of Hospital Pharmacy outline the cost benefits of the non-steroidal anti-androgen bicalutamide 150mg for the treatment of locally advanced prostate cancer. By delaying disease progression in patients with locally advanced prostate cancer, bicalutamide 150mg reduces the additional healthcare costs associated with treating advanced disease.



The paper by Dr Heather Payne, Middlesex Hospital UCL, London states that bicalutamide 150mg impacts less on healthcare budgets compared to other types of cancer treatments.1* An analysis of the cost-effectiveness of bicalutamide 150mg based on the first analysis of the Early Prostate Cancer (EPC) Trial, shows that its estimated cost-effectiveness per quality-adjusted life year (£10,067) falls well below the commonly used threshold for cost-effectiveness (£29,212) and compares well with the cost-utilities of other approaches used in oncology.2,3

The cost of bicalutamide 150mg (administered for three years) plus radical prostatectomy or radiotherapy for locally advanced prostate cancer is also significantly lower compared to the cost of other oncology treatments.2,3


Progression of locally advanced prostate cancer can result in costly complications such as bone metastases and serious skeletal complications.4

In addition, Dr Payne highlights in her paper, that bicalutamide 150mg gives a significant improvement in progression-free survival in patients with locally advanced disease, reducing the risk of objective disease progression by 42% in radiotherapy patients, 47% in watchful waiting patients, and 29% in radical prostatectomy patients.5

As well as being as effective as castration in prolonging survival in non-metastatic prostate cancer6, bicalutamide 150mg has significant quality-of-life benefits, with improvements over castration-based therapies in terms of maintaining bone mineral density, physical capacity and sexual activity.6,7 A recent study of the risk of osteoporosis in men with non-metastatic prostate cancer revealed that those who were treated with bicalutamide 150mg maintained bone mineral density (BMD), whilst those who received castration were associated with a progressive loss of BMD, which can result in costly complications such as increased risk of fractures.7

Dr Payne concludes: “Bicalutamide 150mg is a cost-effective therapy for patients with locally advanced prostate cancer, delaying disease progression, and offers a valuable alternative to castration in this setting”.

Bicalutamide 150mg is indicated in the UK in patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO), as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Bicalutamide 150mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.8

*Data is based on UK NHS costs and may vary in other countries

References:

1. Payne, H. The value of delaying disease progression with bicalutamide (‘Casodex’) 150mg in locally advanced prostate cancer. European Journal of Hospital Pharmacy. 2004.

2. Moeremans K, Caekelbergh K, Annemans L. Cost-effectiveness analysis of bicalutamide (CasodexTM) for adjuvant treatment of early prostate cancer. Value Health 2004; 7: 472-81.

3. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ.

Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18:3302-17.

4. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer,

metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226-32.

5. Wirth M et al. Bicalutamide (Casodex) 150mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5.4 years. J Urol. 2004; 172: 1865–1870.

6. Iversen P, Tyrell CJ, Kaisary AV et al Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J.Urol 2000; 164: 1579-1582.

7. Sieber PR, Keiller DL, Kahnoski RJ et al Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Urology 2004; 171: 2272-6.

8. AstraZeneca; Casodex (bicalutamide)150mg Summary of Product Characteristics.

Bea Shake | alfa
Further information:
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Staying in Shape

16.08.2018 | Life Sciences

Diving robots find Antarctic seas exhale surprising amounts of carbon dioxide in winter

16.08.2018 | Earth Sciences

Protein droplets keep neurons at the ready and immune system in balance

16.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>